Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

Sebastian Stintzing,Kathrin Heinrich,David Tougeron,Dominik Paul Modest,Ingo Schwaner,Jan Euker,Rudolf Pihusch,Martina Stauch,Florian Kaiser,Christoph Kahl,Meinolf Karthaus,Christian Mueller,Christof Burkart,Anke Reinacher-Schick,Stefan Kasper,Ludwig Fischer von Weikersthal,Beate Krammer-Steiner,Gerald W. Prager,Julien Taieb,Volker Heinemann

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

2021

3502Background: FIRE-4.5 (AIO KRK-0116) compared FOLFOXIRI plus either cetuximab or bevacizumab in BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients not treated for metastatic disease ...

Keywords:

Bevacizumab
Medicine
BRAF V600E
Internal medicine
Colorectal cancer
Oncology
FOLFOXIRI
Cetuximab
first line treatment
Randomized controlled trial

Correction
Source
Cite
Save

References

Citations